Erratum to: Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
Erratum to: Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
复制标题
勘误表：雷沙吉兰和司来吉兰治疗帕金森病的疗效：一项为期 3 年的头对头回顾性病例对照研究
作者：
E. Cereda;R. Cilia;M. Canesi;S. Tesei;C. Mariani;A. Zecchinelli;G. Pezzoli
B 型单胺氧化酶 (MAO-B) 抑制剂，例如司来吉兰和雷沙吉兰，可用作左旋多巴单一疗法或辅助疗法治疗帕金森病 (PD)。 MAO-B 抑制剂的长期疗效数据有限，迄今为止尚无头对头比较。这项病例对照回顾性研究的目的是分析帕金森研究所（意大利米兰）6年期间（2009-2015）的帕金森病患者的数据，并比较司来吉兰和雷沙吉兰对左旋多巴治疗结果的影响。使用司来吉兰 (n = 85) 或雷沙吉兰 (n = 85) 治疗 3 年的 PD 患者以及从未接受过 MAO-B 抑制剂的对照组患者 (N = 170) 在基线评估时进行性别、病程 (±1 年) 和年龄 (±1 年) 匹配（比例 1:1:2）。统一 PD 评定量表和 Hoehn-Yahr 分期系统用于临床比较。基线时，平均 PD 持续时间为 6.5 年，所有三组的临床特征相当。经过大约 37 个月的平均随访，三组之间运动和非运动症状的临床进展没有差异。然而，与未使用 MAO-B 抑制剂的患者相比，使用 MAO-B 抑制剂的左旋多巴日剂量变化降低约 2 倍（p < 0.001），并且运动障碍评分较低（p = 0.028）。司来吉兰和雷沙吉兰之间没有观察到组内差异。长期使用 MAO-B 抑制剂可显着减少 PD 患者左旋多巴的需要量，并降低运动障碍的发生频率。司来吉兰和雷沙吉兰在控制优化治疗的 PD 患者运动症状方面具有相同的功效。
Monoamine oxidase type B (MAO-B) inhibitors, such as selegiline and rasagiline, can be used as monotherapy or adjuvant therapy to levodopa in Parkinson’s disease (PD). Data on long-term efficacy of MAO-B inhibitors are limited with no head-to-head comparison available to date. The aim of this case–control retrospective study was to analyze data from patients with PD attending the Parkinson Institute (Milan, Italy) over a 6-year period (2009–2015) and compare the effects of selegiline and rasagiline on levodopa treatment outcomes. Patients with PD treated with either selegiline (n = 85) or rasagiline (n = 85) for 3 years as well as a control group of patients (N = 170) who have never received MAO-B inhibitors, were matched for gender, disease duration (±1 year) and age (±1 year) at baseline assessment (ratio 1:1:2). The Unified PD Rating Scale and the Hoehn–Yahr staging system were used for clinical comparisons. At baseline, mean PD duration was 6.5 years and clinical features were comparable across all three groups. After a mean follow-up of approximately 37 months, no differences in clinical progression of motor and non-motor symptoms were observed between the three groups. However, MAO-B inhibitor use was associated with ~2-fold lower change in daily dose of levodopa (p < 0.001) and lower dyskinesia scores (p = 0.028) than non-users. No intra-class differences were observed between selegiline and rasagiline. Long-term use of MAO-B inhibitors resulted in a significant reduction in levodopa requirements and a lower frequency of dyskinesias in patients with PD. Selegiline and rasagiline had equal efficacy in controlling motor symptoms in PD patients on optimized therapy.
影响因子：
158.5
作者：
SHOULSON, I;FAHN, S;PELUSIO, RM
通讯作者：
PELUSIO, RM